Impulse control disorders and dopamine receptor agonism in Parkinson's disease patients: Clinical implications.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanisms, formulation differences, and receptor selectivity without systematic review methodology.
PubMed 41387037 · doi:10.1016/j.parkreldis.2025.108147
What was done
The authors conducted a review examining the relationship between dopamine receptor subtype selectivity (specifically D3 receptor agonism), drug formulation types (extended release versus immediate release), and the risk of impulse control disorders (such as compulsive shopping, pathological gambling, and hypersexuality) in Parkinson's disease patients receiving dopamine agonists.
What was found
The abstract reports no numerical data, effect estimates, or statistical values. It reports a qualitative association where D3 receptor agonism is more consistently linked to increased impulse control disorder risk than agents with broader dopamine receptor profiles. Differences between extended-release and immediate-release formulations are also identified as potential contributors to risk variance.
Why it matters
Impulse control disorders present a major clinical burden during dopamine agonist therapy in Parkinson's disease; identifying whether specific receptor targets or pharmacokinetics alter risk helps refine drug selection and dosing strategies.
Limits
This is a narrative review with no search strategy, study counts, or quantitative synthesis reported in the abstract. No absolute or relative risk figures are provided, and confounding between receptor selectivity, drug formulation, and baseline patient risk factors cannot be ruled out.
Cited by
- supports Parkinson's medications that increase dopamine levels can alter risk aversion and cause patients to develop hypercompulsive gambling as a side effect.